DK0541692T3 - Herpes simplex virus VP-16-vacciner - Google Patents

Herpes simplex virus VP-16-vacciner

Info

Publication number
DK0541692T3
DK0541692T3 DK91914945T DK91914945T DK0541692T3 DK 0541692 T3 DK0541692 T3 DK 0541692T3 DK 91914945 T DK91914945 T DK 91914945T DK 91914945 T DK91914945 T DK 91914945T DK 0541692 T3 DK0541692 T3 DK 0541692T3
Authority
DK
Denmark
Prior art keywords
herpes simplex
simplex virus
vaccines
compositions
hsv
Prior art date
Application number
DK91914945T
Other languages
English (en)
Inventor
Rae Lynn Burke
Rose E Sekulovich
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DK0541692T3 publication Critical patent/DK0541692T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91914945T 1990-08-02 1991-07-30 Herpes simplex virus VP-16-vacciner DK0541692T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56152890A 1990-08-02 1990-08-02
PCT/US1991/005403 WO1992002251A1 (en) 1990-08-02 1991-07-30 Herpes simplex virus vp16 vaccines

Publications (1)

Publication Number Publication Date
DK0541692T3 true DK0541692T3 (da) 1999-11-01

Family

ID=24242345

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91914945T DK0541692T3 (da) 1990-08-02 1991-07-30 Herpes simplex virus VP-16-vacciner

Country Status (12)

Country Link
US (2) US5714152A (da)
EP (1) EP0541692B1 (da)
JP (3) JP3005292B2 (da)
AT (1) ATE179614T1 (da)
CA (1) CA2088600C (da)
DE (1) DE69131200T2 (da)
DK (1) DK0541692T3 (da)
ES (1) ES2134197T3 (da)
GR (1) GR3030834T3 (da)
IE (1) IE912744A1 (da)
PT (1) PT98565B (da)
WO (1) WO1992002251A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9119940D0 (en) * 1991-09-18 1991-10-30 Hare Peter F J O Polypeptide inhibitor of viral replication
US5965354A (en) * 1995-07-28 1999-10-12 Chiron Corporation Herpes simplex virus diagnostics
US5980912A (en) * 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
EP0984790A1 (en) 1997-06-02 2000-03-15 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6087166A (en) * 1997-07-03 2000-07-11 Basf Aktiengesellschaft Transcriptional activators with graded transactivation potential
DE69933200T2 (de) * 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
KR20010085348A (ko) 1998-08-07 2001-09-07 추후보정 면역능을 갖는 헤르페스 심플렉스 바이러스 항원 및 이를이용하는 방법
US6860615B2 (en) * 1999-01-06 2005-03-01 Armament Systems And Procedures, Inc. LED flashlight with integral keyring clip
US6569616B1 (en) * 1999-07-29 2003-05-27 Wisconsin Alumni Research Foundation Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
JP2003512305A (ja) 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
ATE488249T1 (de) 2001-07-31 2010-12-15 Univ Washington Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
KR100420501B1 (ko) * 2001-09-26 2004-03-02 한국지질자원연구원 벤토나이트로부터 몬모릴로나이트 광물의 분리·회수 방법
CA2486553C (en) * 2002-06-17 2012-01-10 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US9044447B2 (en) 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
MY159500A (en) * 2009-05-22 2017-01-13 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2013078299A1 (en) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ, インコーポレイテッド ヘルペスを処置するための方法および組成物
US10745931B1 (en) 2019-08-14 2020-08-18 Premises Innovations Llc Self-rightening post system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US4891315A (en) * 1982-10-25 1990-01-02 American Cyanamid Company Production of herpes simplex viral porteins
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
DE3461928D1 (en) * 1983-06-23 1987-02-12 Person Stanley Immunologically reactive non-glycosylated amino acid chains of glycoprotein b of herpes virus types 1 and 2
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
JPS6051120A (ja) * 1983-08-31 1985-03-22 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニットワクチン
US4642333A (en) * 1983-09-16 1987-02-10 Stanley Person Immunologically reactive non-glycosylated amino acid chains of glycoprotein B of herpes virus types 1 and 2
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
ATE230798T1 (de) * 1984-04-06 2003-01-15 Chiron Corp Rekombinanter herpes simplex gb-gd-impfstoff
FR2563434B1 (fr) * 1984-04-25 1986-07-25 Transgene Sa Vaccin contre la rage et procede pour sa preparation
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
JPH0668B2 (ja) * 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
ATE136468T1 (de) * 1986-10-20 1996-04-15 Chiron Corp Impfstoff zur behandlung von hsv
GB8917029D0 (en) * 1989-07-25 1989-09-13 Marie Curie Memorial Foundatio Polypeptide inhibitor of viral replication

Also Published As

Publication number Publication date
GR3030834T3 (en) 1999-11-30
WO1992002251A1 (en) 1992-02-20
JP2002136297A (ja) 2002-05-14
EP0541692B1 (en) 1999-05-06
DE69131200D1 (en) 1999-06-10
EP0541692A4 (en) 1993-12-08
PT98565A (pt) 1992-06-30
CA2088600C (en) 1999-11-16
EP0541692A1 (en) 1993-05-19
DE69131200T2 (de) 1999-12-09
JPH06502989A (ja) 1994-04-07
IE912744A1 (en) 1992-02-12
ES2134197T3 (es) 1999-10-01
US5795579A (en) 1998-08-18
US5714152A (en) 1998-02-03
JP3005292B2 (ja) 2000-01-31
ATE179614T1 (de) 1999-05-15
CA2088600A1 (en) 1992-02-03
JPH11308998A (ja) 1999-11-09
PT98565B (pt) 1999-01-29

Similar Documents

Publication Publication Date Title
DK0541692T3 (da) Herpes simplex virus VP-16-vacciner
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
NL300185I1 (nl) Acellulair vaccin.
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
IL104780A0 (en) Sulfonic acid derivatives in the treatment of viral diseases
ATE190659T1 (de) Rekombinante immuntoxine
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
ATE220557T1 (de) Darmprotozoen-impfstoffe
DK0545991T3 (da) Peptider, der blokerer infektioner med human immundefektvirus, og fremgangsmåder til anvendelse deraf
DK0459176T3 (da) Oligophosphater med antiviral virkning
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
MX9400210A (es) Tratamiento de infecciones virales.